Disappointedly, our ChIP assay showed that the ER did not interact with the CDK2 or CDK4 promoter regions, suggesting that BC-N102 downregulates the expression of CDK2 and CDK4 independent of the ER in breast cancer cell lines. Here, CDK4 is linked to breast carcinoma.